Abstract
Objective: To compare the clinical efficacy and tolerability of butenafine 1% in cream with terbinafine 1% in cream in the treatment of plantar or moccasin-type tinea pedis (athlete’s foot).
Design and Setting: This was a placebo-controlled, double-blind study.
Patients and Participants: 60 men aged between 18 and 60 years (mean 35.4 years) with a mean duration of disease of 28.4 weeks, positive mycology and culture-confirmed tinea pedis participated in the study.
Methods: The participants were sequentially randomised into three parallel groups (butenafine cream, terbinafine cream and placebo). Each patient was given a precoded 25g tube and instructed to apply the trial medication to all tinea pedis lesions once daily at bedtime for 5 consecutive days per week (maximum of 2 weeks’ active treatment). Patients were examined on a weekly basis. Cure was defined as negative potassium hydroxide test results and negative fungal culture (mycological cure). Participants cured during the treatment were allowed to discontinue the treatment.
Results: By the end of the treatment 60% of all patients were cured. Butenafine cured 18 (90%) patients at 1 week and no further patients at 2 weeks. Terbinafine cured no patients at 1 week and 16 (80%) patients at 2 weeks. Placebo cured no patients at 1 week and 2 (10%) patients at 2 weeks (p < 0.0001, butenafine and terbinafine vs placebo at 2 weeks). None of the patients reported any drug-related adverse events and no patients discontinued treatment.
Conclusion: Butenafine 1% in cream is well tolerated and comparatively better than terbinafine 1% in cream or placebo to cure plantar or moccasin-type tinea pedis in men. Further clinical studies appear warranted.
Similar content being viewed by others
References
Leyden JL. Tinea pedis: pathophysiology and treatment. J Am Acad Dermatol 1994; 31 (3 Pt 2): S31–S33
Odom RB. Pathophysiology of dermatophyte infections. J Am Acad Dermatol 1993; 28 Suppl.: S2–S7
Raboobee N, Aboobaker J, Peer AK. Tinea pedis et unguium in the Muslim community of Durban, South Africa. Int J Dermatol 1998; 37: 759–65
Petranyi G, Ryder NS, Stütz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239–41
Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 782–5
Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997; 36 (2 Pt 1) S3–S8
Tschen E, Elewski B, Gorsulowsky DC, et al. Treatment of interdigital tina pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36 (2 Pt 1): S9–S14
Stütz A. Synthesis and structure-activity correlations within allylamine Antimycotics. Ann N Y Acad Sci 1988; 554:46–62
Arika T, Yokoo M, Yamaguchi H. Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs. Antimicrob Agents Chemother 1992; 36: 2523–5
Reyes BA, Beutner KR, Cullin SI, et al. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol 1997; 37: 450–3
Nahm WK, Orengo I, Rosen T. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J Am Acad Dermatol 1999; 41: 203–6
Tsuyuki S, Ito M, Unno T, et al. Clinical usefulness of butenafine chloride on tinea pedis: comparison study with clotrimazole. Acta Dermatol 1990; 85: 299–306
Evans EG, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in the treatment of tinea pedis. BMJ 1993; 307: 645–7
Bergstresser PR, Elewski BE, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4 week treatment regimens. J Am Acad Dermatol 1993; 28: 648–51
Wahid Z, Butt J, Nishtar R. Multicenter double-blind study of efficacy and safety of terbinafine 1% cream compared with bifonazole 1% cream in patients with tinea pedis moccasin type. J Dermatol Treatment 1997; 8: 225–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Syed, T.A., Hadi, S.M., Qureshi, Z.A. et al. Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis. Clin. Drug Investig. 19, 393–397 (2000). https://doi.org/10.2165/00044011-200019060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200019060-00001